Tempus reported preliminary fourth‑quarter revenue of roughly $367 million, an 83% increase year‑over‑year, citing testing growth as the primary driver and topping Wall Street estimates. The company attributed $266 million of Q4 revenue to diagnostics — a 121% rise — and said full‑year 2025 revenue should reach about $1.27 billion. Tempus also reported rapid expansion in its Insights business and announced a $1.1 billion total contract value from over 70 customers; the company is scheduled to present at JP Morgan's healthcare conference.